CONSENSUS GUIDELINES FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Autori:
Nadan Rustemović, Jasminka Jakić-Razumović, Borislav Belev, Branka Petričević, Mate Škegro, Emil Kinda, Goran Augustin, Irena Hrstić, Rajko Ostojić, Ranka Štern-Padovan, Damir Vrbanec
Sažetak
Gastrointestinalni stromalni tumori najčešći su mezenhimalni tumori probavnog trakta. Klinički su uglavnom asimptomatski. Najčešće se slučajno otkrivaju prilikom endoskopskih i radioloških pregleda. Oko 80% GIST-ova pokazuje KIT (CD 117-antigen) gensku mutaciju većinom na lokaciji eksona 11, a rjeđe na eksonima 9, 13 ili 17, što rezultira nekontroliranim KIT-signalima. Saznanja o ovim mutacijama omogućila su razvoj efikasne sistemske terapije koja djeluje po tipu inhibicije aktivnosti receptora tirozin kinaze, a prototip joj je imatinib mesilat. S ciljem da se u Hrvatskoj osigura standardizirani pristup racionalnom i efikasnom dijagnostičkom postupku te liječenju organiziran je multidisciplinarni sastanak. Rezultati sastanka prikazani su u tekstu koji slijedi.
Summary
Gastrointestinal stromal tumors are the most common mesenchymal tumors in gastrointestinal tract. They are often asymptomatic and discovered incidentally during endoscopic or barium studies. About 80% GISTs have a KIT (CD 117 antigen) gene mutation. Most affect exon 11, less commonly exon 9,13 or 17, that results in uncontrolled KIT signaling. This led to effective systemic therapies in the form of small molecule inhibitors of the receptor tyrosine kinase such as imatinib mesylat. With the purpose of providing standardized approach to rational and effective diagnostic and treatment algorithm in Croatia, a multidisciplinary session was organized. Results of the session are given in the form of Consensus guidelines.
